欣龙控股 原材料?
欣龙控股 原材料?
Alpha Pro Tech" data-reactid="21">阿尔法专业技术
Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Bulk orders are expected as the disease progresses." data-reactid="22">阿尔法专业技术有限公司(纽约证券交易所:APT)制造口罩和防护服装--在中国已经有很高的需求。随着疾病的发展,预计会有大量订单。
Lakeland Industries" data-reactid="23">莱克兰工业
Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients. Lakeland has historically surged during outbreaks and proved a favored supplier amid the Ebola outbreak." data-reactid="24">莱克兰工业公司(纳斯达克:湖)还为高风险的工作人员(如医疗专业人员和公共卫生官员)生产防护衣物,让他们暴露在病人面前。莱克兰历史在疫情爆发期间激增,在埃博拉爆发期间被证明是最受欢迎的供应者。
See Also: A History Of Coronavirus Outbreaks And The Stock Market" data-reactid="25">另见:冠状病毒爆发的历史与股票市场
Co-Diagnostics" data-reactid="26">共诊
Co-Diagnostics Inc (NASDAQ: CODX) is developing a test for the new coronavirus strain. Chinese officials and fearful travel companies demonstrate high demand for accurate diagnostics, as fever has proven an unreliable indicator of disease." data-reactid="27">犹他州医药公司共同诊断公司(纳斯达克:CODX)是发展中对新冠状病毒株的测试。中国官员和忧心忡忡的旅游公司对准确诊断的需求很高,因为发烧已经被证明是不可靠的疾病指标。
Vir Biotech" data-reactid="28">VIR生物技术
Vir Biotechnology Inc (NASDAQ: VIR) includes an antibody for another coronavirus strain, but management is testing to determine efficacy on the Wuhan strain." data-reactid="29">投资组合VIR生物技术公司(纳斯达克:维尔)包括另一种冠状病毒株的抗体,但管理部门正在测试,以确定对武汉株的效力。
维珍在一份新闻稿中说:“我们有一个多个全人类mAb库,可以结合和中和冠状病毒,如SARS和MERS,”首席科学官Herbert“Skip”维珍在一份新闻稿中说。“.其中一些单克隆抗体能够中和人畜共患病冠状病毒,我们相信有可能治疗和预防武汉冠状病毒。我们亦正研究分离这种病毒的新单克隆抗体。“
BioCryst" data-reactid="31">生物冷冻
BioCryst Pharmaceuticals, Inc.'s (NASDAQ: BCRX) galidesivir is in a Phase 1 study for a range of viruses, including coronaviruses. The early stage of development may prohibit material contribution in the immediate outbreak, but BioCryst may be able to lend some useful data." data-reactid="32">生物冷冻制药公司(纳斯达克:BCRX)Galidervir正在对包括冠状病毒在内的一系列病毒进行第一阶段的研究。早期的发展阶段可能禁止在立即爆发中作出实质性贡献,但BioCryst可能能够提供一些有用的数据。
Inovio" data-reactid="33">诺维奥
Inovio Pharmaceuticals Inc (NASDAQ: INO) is developing a vaccine to treat the MERS strain of coronavirus. While the drug has passed only Phase 1 benchmarks, management may be able to contribute its research toward the Wuhan coronavirus effort. It has already joined forces with the Coalition for Epidemic Preparedness Innovations toward this end." data-reactid="34">Inovio制药公司(纳斯达克:伊诺)正在研制一种治疗MERS冠状病毒株的疫苗。虽然该药物仅通过了第一阶段的基准,但管理层可能能够为武汉的冠状病毒研究做出贡献。它已为此目的与防疫创新联盟联合起来。
Novavax" data-reactid="35">诺瓦瓦克斯
Novavax, Inc. (NASDAQ: NVAX) has launched a program for the Wuhan-coronavirus vaccine. It already boasts success in vaccine development for the MERS and SARS strains." data-reactid="36">诺瓦瓦克斯公司(纳斯达克:NVAX)发射武汉冠状病毒疫苗计划。它已经在MERS和SARS毒株的疫苗开发方面取得了成功。
NanoViricides" data-reactid="37">纳米病毒
NanoViricides Inc (NYSE: NNVC) produces nan-medicines to fight virus such as swine flu and bird flu. It also has early-stage programs for Dengue viruses and Ebola and once dabbled in a MERS candidate." data-reactid="38">纳米病毒公司(纽约证券交易所:NNVC)生产抗病毒药物,如猪流感和禽流感。它也有登革热病毒和埃博拉病毒的早期项目,并且曾经涉足过一位MERS候选人。
Cleveland BioLabs" data-reactid="39">克利夫兰生物实验室
Cleveland BioLabs, Inc. (NASDAQ: CBLI) develops immune-receptor activators for vaccines targeting various types of infection. Its vaccine adjuvant is currently in Phase 1 trials." data-reactid="40">肿瘤学药学克利夫兰生物实验室公司(纳斯达克:CBLI)开发针对不同类型感染的疫苗的免疫受体激活剂。其疫苗佐剂目前正处于试验阶段。
Cerus" data-reactid="41">塞鲁斯
Cerus Corporation (NASDAQ: CERS) uses proprietary technology to inactivate the SARS strain, and it's looking to adapt its approach to the novel Wuhan strain." data-reactid="42">塞鲁斯公司(纳斯达克:核证的排减量)使用专有技术灭活SARS病毒株,并试图使其方法适应武汉新品系。
Moderna" data-reactid="43">现代
Moderna Inc (NASDAQ: MRNA) received new funding from vaccine alliance CEPI to accelerate its work on a coronavirus vaccine, and it has joined forces with the Coalition for Epidemic Preparedness Innovations on a vaccine approach." data-reactid="44">现代公司(纳斯达克:mRNA)从疫苗联盟CEPI获得新的资金以加速它在冠状病毒疫苗上的工作,它还与防疫创新联盟联合采取疫苗办法。
Aethlon" data-reactid="45">艾斯隆
Aethlon Medical, Inc. (NASDAQ: AEMD) treats viral infections with its hemopurifier. The product boosts immune defenses by capturing otherwise poorly-detected circulating viruses. It is presently in clinical studies." data-reactid="46">Aethlon医疗公司(纳斯达克:AEMD)用血液分析仪治疗病毒感染。该产品通过捕获检测不佳的循环病毒来增强免疫防御能力。目前正在进行临床研究。
AstraZeneca" data-reactid="47">阿斯利康
AstraZeneca plc (NYSE: AZN) said it had plans in place for an event such as this, but it awaits direction from the World Health Organization before acting." data-reactid="48">阿斯利康公司(纽约证券交易所:AZN)说它已经为这样的事件制定了计划,但是在采取行动之前,它还在等待世界卫生组织的指示。
阿斯利康(AstraZeneca)首席执行官帕斯卡尔·索里奥(PascalSoriot)对CNBC表示:“在这一点上,它看起来真的很有“我们在中国有很大的业务--我们是中国的第一大制药公司,我们雇佣了1.6万名员工--因此,正如你所想象的那样,我们非常关心这个问题,我们会对此进行监控,但看起来它暂时已经被控制住了。”
Cocrystal Pharma" data-reactid="50">晶体药物
Cocrystal Pharma Inc (NASDAQ: COCP) has licensed a preclinical compound that it intends to develop into a coronavirus therapy. It claims all royalty rights to the antiviral drug." data-reactid="51">科晶制药有限公司(纳斯达克:COCP)已经批准了一种临床前化合物,它打算发展成为一种冠状病毒疗法。它声称拥有抗病毒药物的所有版权。
炒题材的时候楼主在谈基本面,快醒醒。
其实估值还是有点高了
公司员工已达112人,达到百人规模。不可小觑,后面召人,24小时候开工,量价齐升,想象力丰富
APT周四表示,自1月27日以来,该公司已预订了约1,410万美元的面罩订单.这与APT两周前在2月13日公布的1,040万美元相比有所增加。
这家防护装备制造商正在增加N-95面罩的生产,理由是冠状病毒爆发(现在被称为Covid-19)带来的需求更高。
周三,APT公布稀释后每股收益为3美分,低于一年前的5美分。收入为1,092万美元,而一年前为1,096.9万美元。目前还没有对这只曾经交易清淡的股票的估值。
该公司称,由于产品结构的变化,2019年毛利率下降。但该公司预计,2020年毛利率将有所改善,“因为N-95面罩的毛利率明显高于我们的总体毛利率。”
在招韭菜吗···
有点长,我吃点东西回来看